Anti-SARS-CoV-2 antibody-containing plasma improves outcome in patients with hematologic or solid cancer and severe COVID-19: a randomized clinical trialClaudia M. Denkinger, Michael Schmitt, Maike Janssen et al.|Nature Cancer|2022Cited by 62
PDGFRα/β expression correlates with the metastatic behavior of human colorectal cancer: A possible rationale for a molecular targeting strategyCarl Christoph Schimanski|Oncology Reports|2008Cited by 37
Anti-SARS-CoV-2 antibody containing plasma improves outcome in patients with hematologic or solid cancer and severe COVID-19 via increased neutralizing antibody activity – a randomized clinical trialClaudia M. Denkinger, Michaël Schmitt, Maike Janssen et al.|medRxiv|2022Cited by 4
Contents Vol. 48, 2012Steffen Maier, Druck Reinhardt Druck Basel, Anke Mayer et al.|European Surgical Research|2012Cited by 0
1142. Plasma with high titers of anti-SARS-Cov2 antibodies improves outcome of COVID-19 in patients with hematological malignancy and cancer in a randomized controlled trialClaudia M. Denkinger, Carsten Müller‐Tidow, Maike Janssen et al.|Open Forum Infectious Diseases|2022Cited by 0